The resolution draft below addresses both the tactical issue of drug-price transparency (Bill A.08046) and the strategic issue of choice.
Whereas, the current Congress has overlooked prescription drug prices in both the House’s American Health Care Act and all versions of the Senate’s Better Care Reconciliation Act;
Whereas, a Kaiser poll conducted in April 2017 shows that a large percentage of Americans — including Democrats, Republicans and independent — support multiple actions to control drug prices;
Whereas, there are no competitive market forces driving prescription drug prices;
1) Resolution by the (name of County or entity) in support of the concept and intent of bill A.08046 in New York State Assembly and its companion bill S.6629 in the New State Senate that would mandate price disclosure prior to a prescription being filled; and would promote drug price transparency; as well as, would allow consumers both discretion and the convenience to shop around, thereby returning control to the consumer;
1 b) Resolution by the (name of County or entity) call on county representatives in the Assembly and Senate to co-sponsor the concept and intent of bill A.08046 in New York State Assembly and its companion bill S.6629 in the New York State Senate.
2) Resolution by the (name of County or entity) in support of calling for New York State to pilot its own prescription drug dispensary. The pilot program would compete with existing pharmacies, thereby providing real choice to consumers and would allow for the aggregation of empirical data for larger rollout; the advent of consumer transparency and choice are strategic imperatives to reduce drug prices;